Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries

被引：0
|
作者：
P. A. Laires
F. Exposto
R. Mesquita
A. P. Martins
L. Cunha-Miranda
J. E. Fonseca
机构：
[1] Merck Sharp & Dohme,Outcomes Research
[2] IMS Health,Medical Affairs
[3] Merck Sharp & Dohme,Department of Rheumatology
[4] Instituto Português de Reumatologia,Rheumatology Research Unit
[5] Instituto de Medicina Molecular da Faculdade de Medicina da Universidade de Lisboa,undefined
来源：
The European Journal of Health Economics | 2013年 / 14卷
关键词：
Rheumatoid arthritis; Treatment access; Biologics; Portugal; I11;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：875 / 885
页数：10
相关论文
共 50 条
  • [1] Patients' access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countries
    Laires, P. A.
    Exposto, F.
    Mesquita, R.
    Martins, A. P.
    Cunha-Miranda, L.
    Fonseca, J. E.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (06): : 875 - 885
  • [2] PATIENT ACCESS TO BIOLOGICS IN RHEUMATOID ARTHRITIS: THE VIEWS OF HEALTH CARE STAKEHOLDERS IN PORTUGAL
    Laires, P.
    Mesquita, R.
    Veloso, L.
    Martins, A. P.
    Cernadas, R.
    Fonseca, J. E.
    VALUE IN HEALTH, 2012, 15 (07) : A453 - A453
  • [3] Access to timely care in Portugal as compared to other European countries
    Pereira, Manuel Goncalves
    Stephan, Astrid
    Verhey, Frans
    de Vugt, Marjolein
    Wolfs, Claire
    Handels, Ron
    Verbeek, Hilde
    Kerpershoek, Liselot
    Bieber, Anja
    Meyer, Gabriele
    Marques, Maria
    Barrios, Helena
    Balsinha, Conceicao
    Woods, Robert
    Wimo, Anders
    Selbaeck, Geir
    Irving, Kate
    Zanetti, Orazio
    INTERNATIONAL PSYCHOGERIATRICS, 2015, 27 : S35 - S36
  • [4] Characterizing Norwegian rheumatoid arthritis patients using the QUEST-RA protocol for comparison with other European countries
    Haugeberg, G.
    Wilberg, E.
    Gjelberg, H.
    Rodevand, E.
    Sokka-Isler, T.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 : 31 - 32
  • [5] EXPLANATORY FACTORS FOR THE RHEUMATOID ARTHRITIS PATIENTS' ACCESS TO BIOLOGICAL AGENTS IN 15 EUROPEAN COUNTRIES
    Laires, P. A.
    Exposto, F.
    Barosa, P.
    Hormigos, B.
    Martins, A. P.
    VALUE IN HEALTH, 2011, 14 (07) : A316 - A316
  • [6] COMPARISON OF COST OF INCIDENT RHEUMATOID ARTHRITIS PATIENTS IN TURKEY WITH SELECTED EUROPEAN COUNTRIES
    Baser, O.
    Rodriguez, N.
    Rodchenko, K.
    VALUE IN HEALTH, 2023, 26 (12) : S57 - S58
  • [7] Current use of biologics and other dmards in a sample of 1579 patients with rheumatoid arthritis receiving routine clinical care in 9 western European countries
    Sokka, T.
    Hetland, M. L.
    Verstappen, S. M. M.
    Gossec, L.
    Ferraccioli, G.
    Cutolo, M.
    Belmonte, M.
    Naranjo, A.
    Minnock, P.
    Bresnihan, B.
    Oding, R.
    Rau, R.
    Pincus, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 502 - 502
  • [8] A comparison between patients with rheumatoid arthritis in the western part of Sweden with or without treatment with biologics
    Bengtsson, K.
    Dehlin, M.
    Hilme, E.
    Kvist, G.
    Rydberg, B.
    Torstenson, T.
    Lindhe, A.
    Wallerstedt, S. M.
    Forsblad-dElia, H.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 42 - 43
  • [9] The Clinical Impact of Overweight in Rheumatoid Arthritis Patients: Comparison Between Korean and Other Countries within the Comora Study
    Shin, Kichul
    Ahn, Eun Young
    Kwon, Hyun Mi
    Choi, In Ah
    Baik, Yeonsoo
    Song, Yeong Wook
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [10] Discontinuation of biologics in patients with rheumatoid arthritis
    Tanaka, Y.
    Hirata, S.
    Saleem, B.
    Emery, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S22 - S27
12345